02534: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma

Grant Status: Open

Grant Amount: $310,790
Erin B. Dickerson, PhD and Antonella Borgatti, DVM, MS; University of Minnesota
July 1, 2019 - June 30, 2022

Sponsor(s): American Belgian Tervuren Club, Inc., American Pointer Club, Australian Shepherd Health and Genetics Institute, Inc.,Briard Club of America Health & Education Trust, Clumber Spaniel Health Foundation, Golden Retriever Foundation, Gordon Setter Club of America, Inc., Health & Rescue Foundation of the Petit Basset Griffon Vendeen Club of America, Irish Setter Club of America Foundation, Irish Setter Club of Milwaukee, Inc., Labrador Retriever Club, Inc., Nespola Charitable Foundation, Old English Sheepdog Club of America, Portuguese Water Dog Foundation, Inc., Rhodesian Ridgeback Charitable Foundation, Rottweiler Health Foundation, Samoyed Club of America Education & Research Foundation, The Kennel Club of Philadelphia, Vizsla Club of America Welfare Foundation

Breed(s): -All Dogs
Research Program Area: Oncology - Hemangiosarcoma
Donate to Support this Research Program Area

Abstract

Co-investigators: David R. Brown, PhD; University of Minnesota, Michael O. Childress, DVM, MS; Purdue University, Jennifer Mahoney, DVM and Pascale Salah; University of Pennsylvania

Canine hemangiosarcoma is a largely incurable cancer in dogs, and treatment approaches to improve outcomes have remained relatively stagnant over the past few decades. Treatment remains a challenge partly because the cancer is frequently detected at an advanced stage and because these tumors are often resistant to chemotherapies. Recently published reports showed that propranolol, a drug used to treat heart disease in humans and dogs, substantially increased the survival time of human angiosarcoma patients when used in combination with standard of care treatments. Propranolol was also shown to sensitize hemangiosarcoma cells to doxorubicin, providing a more effective way to kill tumor cells. Because angiosarcoma is strikingly similar to canine hemangiosarcoma, this multi-institutional clinical trial has been designed to determine the efficacy of propranolol in dogs with hemangiosarcoma when used in combination with surgery and chemotherapy. The main goal of the study is to establish whether propranolol in combination with doxorubicin following surgery improves outcomes for dogs when compared to the use of chemotherapy and surgery alone. The investigators will also evaluate the plasma concentrations of propranolol achieved during dosing to assess whether the levels of propranolol correlate to survival times. If successful, the findings from this approach will be rapidly conveyed to the veterinary community, and the guidelines provided to clinicians for the use of propranolol and doxorubicin for the treatment of canine hemangiosarcoma.

Learn how you can participate in this study!

Publication(s)

None at this time.

Help Future Generations of Dogs

Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.

Learn How to Help

Connect With Us:
Get Canine Health News:
Please leave this field empty
American Kennel Club Canine Health Foundation, Inc

8051 Arco Corporate Dr.
Suite 300
Raleigh, NC 27617
(888)-682-9696

Tax ID# 13-3813813

   2020 GuideStar logo

© 2020 AKC Canine Health Foundation | Privacy Policy | Site Map

Site by Blackbaud, Inc.

Powered by Blackbaud
nonprofit software